HLB innoVation Co.,Ltd.
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 024850.KQ | 0QB8.IL | ASML.NE | 688120.SS | 000100.SZ | 240810.KQ | |
|---|---|---|---|---|---|---|
| Market cap | 496.20B | 526.64B | 836.68B | 102.90B | 101.61B | 3.54T |
| P/E (TTM) | — | 70.0 | 49.9 | 76.7 | 14.9 | — |
| Forward P/E | — | — | — | 44.1 | 8.8 | — |
| Price/book | — | 43.0 | 0.9 | 8.4 | 1.5 | — |
| Dividend yield | — | 1.09% | 0.51% | 0.20% | 1.92% | 0.23% |
| 1-year change | +79.73% | +49.48% | +25.98% | +100.27% | +9.09% | +27.81% |
| Today | −5.22% | −1.79% | −4.41% | +2.48% | −1.07% | −15.74% |
The closest companies by business and industry (Semiconductor Equipment & Materials). Prices may be delayed up to 20 min.
Latest news
All 024850.KQ news ›HLB Innovation's Verismo to Unveil Preclinical Results for Solid Tumor CAR-T
Published 16 Oct.2026 10:10(KST) Verismo Therapeutics, a U.S. subsidiary of HLB Innovation, will present preclinical results for its solid tumor CAR-T therapy at the Society for Immunotherapy of Cancer (SITC 2026) on Novemb
HLB Innovation Subsidiary Demonstrates Differentiation of Solid Tumor CAR-T in Preclinical Study
Verismo Therapeutics, the U.S. subsidiary of South Korea's HLB Innovation, will unveil preclinical results next month for its next-generation CAR-T therapy targeting solid tumors. The company said the study confirmed reduced T-cell…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- asiae.co.kr1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 1 articles, not a forecast.